Axsome Therapeutics Inc


Prices are adjusted according to historical splits.

Axsome Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.26 billion
Book Value:
Revenue TTM:
$144.61 million
Operating Margin TTM:
Gross Profit TTM:
$45.94 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Axsome Therapeutics Inc had its IPO on 2015-11-19 under the ticker symbol AXSM.

The company operates in the Healthcare sector and Biotechnology industry. Axsome Therapeutics Inc has a staff strength of 393 employees.

Stock update

Shares of Axsome Therapeutics Inc opened at $80.38 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $80.14 - $82.39, and closed at $82.21.

This is a +2% increase from the previous day's closing price.

A total volume of 420,994 shares were traded at the close of the day’s session.

In the last one week, shares of Axsome Therapeutics Inc have increased by +0.64%.

Axsome Therapeutics Inc's Key Ratios

Axsome Therapeutics Inc has a market cap of $3.26 billion, indicating a price to book ratio of 20.6587 and a price to sales ratio of 134.7595.

In the last 12-months Axsome Therapeutics Inc’s revenue was $144.61 million with a gross profit of $45.94 million and an EBITDA of $-141259392. The EBITDA ratio measures Axsome Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Axsome Therapeutics Inc’s operating margin was -98.99% while its return on assets stood at -37.45% with a return of equity of -250.92%.

In Q1, Axsome Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Axsome Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-3.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Axsome Therapeutics Inc’s profitability.

Axsome Therapeutics Inc stock is trading at a EV to sales ratio of 121.4737 and a EV to EBITDA ratio of -20.9755. Its price to sales ratio in the trailing 12-months stood at 134.7595.

Axsome Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$389.18 million
Total Liabilities
$100.65 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Axsome Therapeutics Inc ended 2023 with $389.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $389.18 million while shareholder equity stood at $111.81 million.

Axsome Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $100.65 million in other current liabilities, 4000.00 in common stock, $-607551000.00 in retained earnings and $10.31 million in goodwill. Its cash balance stood at $246.52 million and cash and short-term investments were $246.52 million. The company’s total short-term debt was $108,000 while long-term debt stood at $147.62 million.

Axsome Therapeutics Inc’s total current assets stands at $304.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $44.79 million compared to accounts payable of $35.77 million and inventory worth $7.94 million.

In 2023, Axsome Therapeutics Inc's operating cash flow was $-71000.00 while its capital expenditure stood at $71000.

Comparatively, Axsome Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Axsome Therapeutics Inc stock is currently trading at $82.21 per share. It touched a 52-week high of $82.85 and a 52-week low of $82.85. Analysts tracking the stock have a 12-month average target price of $111.08.

Its 50-day moving average was $75.06 and 200-day moving average was $71.68 The short ratio stood at 9.42 indicating a short percent outstanding of 0%.

Around 1849.3% of the company’s stock are held by insiders while 7077.1% are held by institutions.

Frequently Asked Questions About Axsome Therapeutics Inc

The stock symbol (also called stock or share ticker) of Axsome Therapeutics Inc is AXSM

The IPO of Axsome Therapeutics Inc took place on 2015-11-19

Similar Industry Stocks (Biotechnology)

Last Price
Ci&T Inc (CINT)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.


22 Cortlandt Street, New York, NY, United States, 10007